StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3045% above fair value
$27.40−0.14 (-0.51%)

Close on Nov 20, 2026Market cap $156.17BP/E 36.1Yield 6.28%

Pfizer Oncology — Total programs in pipeline by Quarter

Pfizer Oncology — Total programs in pipeline: 56 in Q2 2026.

Latest, Q2 2026
56
Period ended Jun 28, 2026
Change on a year earlier
–
History
4 quarters
Since Q3 2025
Sources
4
Documents cited below

Where the Q2 2026 figure comes from

“R&D Phase 1 Phase 2 Phase 3 Registration Total Oncology (1 of 5) Projects 25 9 20 2 56 Phase of Compound Name Mechanism of Action Indication Submission Type”

Source: Pfizer Official Report — Q2 2026 Pipeline Update Final ↗

Reported in Form 8-K Earnings Release & Pfizer Quarterly Pipeline Update.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up oncology — Total programs in pipeline

Cite this data

StockData. (2026). Pfizer Oncology — Total programs in pipeline, quarterly Q3 2025–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/pipe-ta-onc

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?